Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy

OBJECTIVE: Acquired T790M mutations account for 50%–60% of tyrosine kinase inhibitor (TKI)-resistant mechanisms in EGFR mutation-positive (m+) non-small-cell lung cancer (NSCLC) patients, and re-biopsy is recommended to detect these mutations. We investigated the re-biopsy status and the T790M incid...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hanping, Zhang, Li, Si, Xiaoyan, Zhang, Xiaotong, Wang, Mengzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208793/
https://www.ncbi.nlm.nih.gov/pubmed/30464499
http://dx.doi.org/10.2147/OTT.S174075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208793/
https://www.ncbi.nlm.nih.gov/pubmed/30464499
http://dx.doi.org/10.2147/OTT.S174075

Ejemplares similares